Phase IV Clinical Trial to Evaluate Safety of Eribulin in Patients With Locally Advanced or Metastatic Breast Cancer
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2016
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms ESKIMO
- Sponsors Eisai Korea
- 28 Apr 2016 Status changed from active, no longer recruiting to completed.
- 04 Dec 2015 Planned End Date changed from 1 Dec 2016 to 1 Jan 2016, according to ClinicalTrials.gov record.
- 11 Aug 2015 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016 according to ClinicalTrials.gov record